Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    6 1 0 0


Joint Bone Spine
Volume 71, n° 6
pages 530-535 (novembre 2004)
Doi : 10.1016/j.jbspin.2004.02.006
Received : 22 August 2003 ;  accepted : 4 February 2004
Somatostatin and somatostatin analog scintigraphy: any benefits for rheumatology patients?
 

Michèle Duet a, c, Frédéric Lioté b, c, d,
a Service de Biophysique et de Médecine Nucléaire, Hôpital Lariboisière (Assistance Publique-Hôpitaux de Paris), 2, rue Ambroise-Paré, 75475 cedex 10, France 
b Fédération de Rhumatologie (Centre Vigo Petersen), France 
c UFR Saint Louis-Lariboisière, Université Paris 7, 10, avenue de Verdun, 75010 Paris, France 
d INSERM U606, Hôpital Lariboisière (Assistance Publique-Hôpitaux de Paris), 2, rue Ambroise-Paré, 75475 Paris cedex 10, France 

*Corresponding author.
Abstract

Somatostatin is a hormone that regulates several physiological cell processes via specific receptors expressed throughout the body, in particular by nerve cells, many neuroendocrine cells, and cells mediating inflammation and immune responses. Somatostatin receptor scintigraphy achieved by administration of somatostatin labeled with a γ-emitting isotope has become an integral part of the work-up and treatment-monitoring program in patients with neuroendocrine tumors, most of which overexpress somatostatin receptors. Several studies have convincingly established that somatostatin receptor scintigraphy benefits patients with a number of chronic inflammatory diseases, including sarcoidosis and other granulomatous diseases. In the evaluation of hematological diseases and detection of mesenchymatous tumors manifesting as oncogenic osteomalacia, the preliminary results are sufficiently promising to warrant larger studies aimed at defining the role for this noninvasive whole-body imaging technique. In the treatment area, the development of somatostatin analogs with antisecretory and antiproliferative effects has radically changed the management of gastroenteropancreatic neuroendocrine and pituitary tumors. The antiinflammatory and analgesic effects of these drugs remain incompletely understood, but may prove useful in a number of autoimmune diseases.

The full text of this article is available in PDF format.

Keywords : Somatostatin, Scintigraphy, Granulomatosis, Inflammation, Mesenchymal tumors



 For this work, there was no conflict of interest with, or pressure from, the companies that market Octreoscan® or somatostatin analogs.



© 2004  Éditions scientifiques et médicales Elsevier SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline